Business Description
Santen Pharmaceutical Co Ltd
NAICS : 325412
ISIN : US80287P1003
Share Class Description:
SNPHY: ADRDescription
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.71 | |||||
| Interest Coverage | 10.88 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 4.91 | |||||
| Beneish M-Score | -3.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.6 | |||||
| 3-Year EBITDA Growth Rate | 21.6 | |||||
| 3-Year EPS without NRI Growth Rate | 46 | |||||
| 3-Year FCF Growth Rate | 65 | |||||
| 3-Year Book Growth Rate | 2.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 17.49 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.63 | |||||
| 9-Day RSI | 55.32 | |||||
| 14-Day RSI | 51.55 | |||||
| 6-1 Month Momentum % | 5.71 | |||||
| 12-1 Month Momentum % | 11.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | |||||
| Quick Ratio | 1.97 | |||||
| Cash Ratio | 1.02 | |||||
| Days Inventory | 135.28 | |||||
| Days Sales Outstanding | 102.57 | |||||
| Days Payable | 124.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| 3-Year Dividend Growth Rate | 5.6 | |||||
| Forward Dividend Yield % | 2 | |||||
| 5-Year Yield-on-Cost % | 2.6 | |||||
| 3-Year Average Share Buyback Ratio | 3.2 | |||||
| Shareholder Yield % | 7.74 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.92 | |||||
| Operating Margin % | 12.33 | |||||
| Net Margin % | 8.64 | |||||
| FCF Margin % | 21.14 | |||||
| ROE % | 8.7 | |||||
| ROA % | 6.15 | |||||
| ROIC % | 11.16 | |||||
| ROC (Joel Greenblatt) % | 26.66 | |||||
| ROCE % | 9.79 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.08 | |||||
| Forward PE Ratio | 15.56 | |||||
| PE Ratio without NRI | 22.08 | |||||
| Shiller PE Ratio | 24.84 | |||||
| Price-to-Owner-Earnings | 13.94 | |||||
| PS Ratio | 2.01 | |||||
| PB Ratio | 2.01 | |||||
| Price-to-Tangible-Book | 2.78 | |||||
| Price-to-Free-Cash-Flow | 9.62 | |||||
| Price-to-Operating-Cash-Flow | 8.33 | |||||
| EV-to-EBIT | 13.22 | |||||
| EV-to-Forward-EBIT | 9.15 | |||||
| EV-to-EBITDA | 8.51 | |||||
| EV-to-Forward-EBITDA | 8.18 | |||||
| EV-to-Revenue | 1.44 | |||||
| EV-to-Forward-Revenue | 1.7 | |||||
| EV-to-FCF | 7.05 | |||||
| Price-to-Projected-FCF | 1.11 | |||||
| Price-to-Median-PS-Value | 0.65 | |||||
| Price-to-Graham-Number | 1.67 | |||||
| Price-to-Net-Current-Asset-Value | 5.91 | |||||
| Earnings Yield (Greenblatt) % | 7.56 | |||||
| FCF Yield % | 11.5 | |||||
| Forward Rate of Return (Yacktman) % | 1.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:SNPHY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Santen Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,037.908 | ||
| EPS (TTM) ($) | 0.495 | ||
| Beta | 0.48 | ||
| Volatility % | 21.62 | ||
| 14-Day RSI | 51.55 | ||
| 14-Day ATR ($) | 0.742027 | ||
| 20-Day SMA ($) | 10.877275 | ||
| 12-1 Month Momentum % | 11.84 | ||
| 52-Week Range ($) | 8.95 - 13 | ||
| Shares Outstanding (Mil) | 342.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Santen Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Santen Pharmaceutical Co Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Santen Pharmaceutical Co Ltd Frequently Asked Questions
What is Santen Pharmaceutical Co Ltd(SNPHY)'s stock price today?
The current price of SNPHY is $10.93. The 52 week high of SNPHY is $13.00 and 52 week low is $8.95.
When is next earnings date of Santen Pharmaceutical Co Ltd(SNPHY)?
The next earnings date of Santen Pharmaceutical Co Ltd(SNPHY) is .
Does Santen Pharmaceutical Co Ltd(SNPHY) pay dividends? If so, how much?
The Dividend Yield %  of Santen Pharmaceutical Co Ltd(SNPHY) is 2% (As of Today), Highest Dividend Payout Ratio of Santen Pharmaceutical Co Ltd(SNPHY) was 1.2. The lowest was 0.2. And the median was 0.46. The  Forward Dividend Yield % of Santen Pharmaceutical Co Ltd(SNPHY) is 2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers